Cosmetics, supplements, agriculture, and beyond
Peptide biomaterials — self-assembling hydrogels and nanofibers — are entering clinical use in hemostasis, wound healing, and tissue engineering. With programmable degradation, bioactive signaling, and batch reproducibility, they address regulatory concerns about animal-derived materials like Matrigel.
Cosmetic peptides represent a $3.2B market growing at 12% annually. Signal peptides, neurotransmitter inhibitors, and carrier peptides target distinct skin biology pathways — but the permeability barrier limits efficacy to 1-5% of applied dose. The delivery system matters as much as the peptide.
Antimicrobial peptides are moving beyond therapeutics into food preservation, crop protection, and aquaculture. With engineered nisin variants now commercial in Europe and AMP-expressing crops showing 73% disease reduction in field trials, the non-pharma peptide market is taking shape.